Monoamine transporter availability in Parkinson's disease patients with or without depression

被引:69
|
作者
Hesse, Swen [1 ]
Meyer, Philipp M. [1 ]
Strecker, Karl [2 ]
Barthel, Henryk [1 ]
Wegner, Florian [2 ]
Oehlwein, Christian [3 ]
Isaias, Ioannis Ugo [2 ]
Schwarz, Johannes [2 ]
Sabri, Osama [1 ]
机构
[1] Univ Leipzig, Dept Nucl Med, D-04103 Leipzig, Germany
[2] Univ Leipzig, Dept Neurol, D-04103 Leipzig, Germany
[3] Specialized Parkinsons Dis Outpatient Ctr, Gera, Germany
关键词
SPECT; Dopamine; Serotonin; Striatum; Midbrain; POSITRON-EMISSION-TOMOGRAPHY; SEROTONIN TRANSPORTERS; STRIATAL DOPAMINE; NEUROPSYCHIATRIC SYMPTOMS; I-123-FP-CIT SPECT; LIMBIC SYSTEM; BETA-CIT; BINDING; IMPAIRMENT; BRAIN;
D O I
10.1007/s00259-008-0979-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Depression is a common symptom in patients suffering from Parkinson's disease (PD) and markedly reduces their quality of life. As post-mortem studies have shown, its presence may reflect extensive cell loss in the midbrain and brainstem with imbalances in monoaminergic neurotransmitters. However, in vivo evidence of specific monoaminergic deficits in depressed PD patients is still sparse. Therefore, we studied PD patients with depression (PD+D) and without depression (PD-D) using high-resolution single-photon emission computed tomography (SPECT) and the monoamine transporter marker [I-123]FP-CIT. A magnetic resonance imaging-based region-of-interest analysis was applied to quantify the specific-to-nondisplaceable [I-123]FP-CIT binding coefficient V(3)aEuro(3) in the striatum, thalamus and midbrain/brainstem regions. PD+D patients had significantly lower V(3)aEuro(3) compared with PD-D patients in the striatum (p < 0.001), thalamus (p=0.002), and midbrain/brainstem (p=0.025). Only PD+D patients without selective serotonin reuptake inhibitor (SSRI) treatment showed lower thalamic and midbrain V(3)aEuro(3) than controls (p < 0.001, p=0.029). In a small sub-group of SSRI-treated PD+D patients neither thalamic V(3)aEuro(3) nor midbrain/brainstem V(3)aEuro(3) differed from those in PD-D patients (p=0.168, p=0.201) or controls (p=0.384, p=0.318). Our data indicate that depression in PD is associated with a more pronounced loss of striatal dopamine transporter availability that is most likely secondary to increased dopaminergic degeneration. In addition, depressed PD patients have a lower availability of midbrain/brainstem monoamine transporters than nondepressed PD patients. These findings provide in vivo evidence in support of the known post-mortem data demonstrating more extensive nerve cell loss in PD with depression and indicate that SPECT imaging can help to identify pathophysiological changes underlying nonmotor symptoms in this common movement disorder.
引用
收藏
页码:428 / 435
页数:8
相关论文
共 50 条
  • [1] Monoamine transporter availability in Parkinson’s disease patients with or without depression
    Swen Hesse
    Philipp M. Meyer
    Karl Strecker
    Henryk Barthel
    Florian Wegner
    Christian Oehlwein
    Ioannis Ugo Isaias
    Johannes Schwarz
    Osama Sabri
    European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36
  • [2] Processing speed is related to striatal dopamine transporter availability in Parkinson's disease
    Vriend, Chris
    van Balkom, Tim D.
    van Druningen, Corne
    Klein, Martin
    van der Werf, Ysbrand D.
    Berendse, Henk W.
    van den Heuvel, Odile A.
    NEUROIMAGE-CLINICAL, 2020, 26
  • [3] Higher dopamine transporter density in Parkinson's disease patients with depression
    Felicio, Andre C.
    Moriyama, Tais S.
    Godeiro-Junior, Clecio
    Shih, Ming C.
    Hoexter, Marcelo Q.
    Borges, Vanderci
    Silva, Sonia M. A.
    Amaro-Junior, Edson
    Andrade, Luiz A. F.
    Ferraz, Henrique B.
    Bressan, Rodrigo A.
    PSYCHOPHARMACOLOGY, 2010, 211 (01) : 27 - 31
  • [4] Decreased pallidal vesicular monoamine transporter type 2 availability in Parkinson's disease: The contribution of the nigropallidal pathway
    Cho, Sang Soo
    Christopher, Leigh
    Koshimori, Yuko
    Li, Crystal
    Lang, Anthony E.
    Houle, Sylvain
    Strafella, Antonio P.
    NEUROBIOLOGY OF DISEASE, 2019, 124 : 176 - 182
  • [5] Neuropsychiatric symptoms and striatal monoamine availability in early Parkinson's disease without dementia
    Oh, Yoon-Sang
    Kim, Jean Hee
    Yoo, Sang-Won
    Hwang, Eo-Jin
    Lyoo, Chul Hyoung
    Lee, Kwang-Soo
    Kim, Joong-Seok
    NEUROLOGICAL SCIENCES, 2021, 42 (02) : 711 - 718
  • [6] Neuropsychiatric symptoms and striatal monoamine availability in early Parkinson’s disease without dementia
    Yoon-Sang Oh
    Jean Hee Kim
    Sang-Won Yoo
    Eo-Jin Hwang
    Chul Hyoung Lyoo
    Kwang-Soo Lee
    Joong-Seok Kim
    Neurological Sciences, 2021, 42 : 711 - 718
  • [7] Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease
    Brighina, Laura
    Riva, Chiara
    Bertola, Francesca
    Saracchi, Enrico
    Fermi, Silvia
    Goldwurm, Stefano
    Ferrarese, Carlo
    NEUROBIOLOGY OF AGING, 2013, 34 (06) : 1712.e9 - 1712.e13
  • [8] Low thalamic monoamine transporter availability is related to excessive daytime sleepiness in early Parkinson's disease
    Yoo, Sang-Won
    Oh, Yoon-Sang
    Ryu, Dong-Woo
    Lee, Kwang-Soo
    Lyoo, Chul Hyoung
    Kim, Joong-Seok
    NEUROLOGICAL SCIENCES, 2020, 41 (05) : 1081 - 1087
  • [9] Higher dopamine transporter density in Parkinson’s disease patients with depression
    Andre C. Felicio
    Tais S. Moriyama
    Clecio Godeiro-Junior
    Ming C. Shih
    Marcelo Q. Hoexter
    Vanderci Borges
    Sonia M. A. Silva
    Edson Amaro-Junior
    Luiz A. F. Andrade
    Henrique B. Ferraz
    Rodrigo A. Bressan
    Psychopharmacology, 2010, 211 : 27 - 31
  • [10] Depression in Parkinson's disease
    Ossowska, Krystyna
    Lorenc-Koci, Elzbieta
    PHARMACOLOGICAL REPORTS, 2013, 65 (06) : 1545 - 1557